Health Discovery Announces Non-Exclusive Worldwide Licensing Agreement with Bruker Daltonics
SAVANNAH, Ga.--(BUSINESS WIRE)--Aug. 1, 2006--
New Capability Assists Researchers and Pharmaceutical Firms in Biomarker Discovery and Validation, Discovering Drug Targets, and Personalized Medicine
Health Discovery Corporation ("HDC") today announced that it has executed a non-exclusive worldwide license agreement with Bruker Daltonics Inc. covering Bruker Daltonics' use of HDC's Support Vector Machine ("SVM") technology in the ClinProTools(TM) clinical proteomics product line. ClinProTools is Bruker Daltonics' state-of-the-art bioinformatics solution for biomarker panel analysis, biofluid profiling, multivariate data analysis of large sample cohorts, classical statistics and sample classification. The agreement provides for an up-front fee and royalties based on sales. Financial terms were not disclosed.
Dr. Herbert A. Fritsche, Professor of Laboratory Medicine at the University of Texas' M.D. Anderson Cancer Center and Chairman of HDC's Science Board, commented: "The combination of HDC's SVM pattern recognition technology with Bruker Daltonics' top-performing mass spectrometry systems - in particular its ClinProt product line - provides a significant advance in the field of biomarker discovery. This new capability will greatly assist diagnostic researchers and pharmaceutical companies in their efforts to discover new drug targets, early diagnostic tests, and companion diagnostics for monitoring drug therapy for personalized medicine."
"HDC is very excited about this new partnership with Bruker Daltonics," said Stephen D. Barnhill, M.D., HDC's Chairman and Chief Executive Officer. "Bruker Daltonics is recognized as a leading innovator and developer of systems for clinical research based on mass spectrometry. Bruker's recognition of HDC's powerful SVM technology enhances its ability to meet the needs of its diverse customer base that includes the world's leading pharmaceutical and biotechnology companies."
Dr. Michael Schubert, Executive Vice President of Bruker Daltonics, stated: "We are pleased to enter into this agreement with HDC, the leader in SVM technology in bioinformatics applications. SVMs are high-performance supervised classification algorithms that can analyze high-dimensional mass spectrometric data from a plurality of sample cohorts. In essence, SVMs allow the mass spectrometer to become a more powerful system, thus complementing the use of other classification algorithms such as our Supervised Neural Network(TM), our QuickClassifier(TM), modified genetic algorithms, and others."
ABOUT HEALTH DISCOVERY CORPORATION (OTC Bulletin Board: HDVY)
Savannah-based Health Discovery Corporation is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker and pathway discovery company providing all aspects of First-Phase Biomarker Discovery. The Company's pattern recognition tools have significant potential in other sizable markets such as radiology, Internet search and spam, homeland security, financial futures, and other areas where analysis of large volumes of complex data is required. For more information, please visit www.healthdiscoverycorp.com.
ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)
Bruker BioSciences Corporation in Billerica, Massachusetts is the parent company of Bruker AXS Inc., Bruker Daltonics Inc. and Bruker Optics, Inc. Bruker AXS is a leading developer and provider of life science, materials research and industrial X-ray analysis tools. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry, and also offers a broad line of nuclear, biological and chemical (NBC) detection products for homeland security. Bruker Optics is a leading developer, manufacturer and provider of research, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technology. For more information, please visit www.bruker-biosciences.com.
CAUTIONARY STATEMENT
Any statements contained in this press release that do not describe historical facts may constitute "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the respective management teams of HDC and Bruker Daltonics believe that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K , our most recent quarterly reports on Form 10-Q, and our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.
MULTIMEDIA AVAILABLE:
www.businesswire.com/cgi-bin/mmg.cgi
CONTACT:
Health Discovery Corporation
Daniel R. Furth, 912-352-7488
drfurth@healthdiscoverycorp.com
www.healthdiscoverycorp.com
or
Bruker BioSciences Corp.
Michael Willett, 978-663-3660, ext. 1411
Investor Relations Officer
ir@bruker-biosciences.com
www.brukerbiosciences.com
SOURCE:
Bruker BioSciences Corp.
